Oncimmune Holdings plc
("Oncimmune" or the "Company", together with its subsidiary "the Group")
Appointment of Administrators
and
Resignation of Nominated Adviser and Joint Brokers
Oncimmune Holdings plc (AIM: ONC.L) today announces that, further to its announcement on 17 March 2025, IPF Invest Co 2 S.A.R.L. ("IPF") has appointed Simon Bonney and James Varney of Arafino Advisory Limited as its joint administrators.
As a result of IPF's appointment of administrators, Cavendish Capital Markets Limited has informed the Company of its resignation as Nominated Adviser and Joint Broker to the Company with immediate effect. Pursuant to AIM Rule 1, if a replacement Nominated Adviser is not appointed within one month from the resignation of the current Nominated Adviser, the admission of the Company's shares to trading on AIM will be cancelled. The Company has no current intention of appointing a replacement Nominated Adviser. Furthermore, the Company announces the resignation of Zeus Capital Limited as Joint Broker with immediate effect.
Any party interested in acquiring any assets of the Group should contact the joint administrators as soon as possible by email at ONC@arafino.com.
For further information:
ONC@arafino.com
About Oncimmune
Oncimmune is a precision medicine company, specialising in analysing immune interactions through the autoantibody profile. Taking a platform approach to generating insights, Oncimmune is partnering with global pharmaceutical and biotech companies, as well as contract research organisations (CROs) to discover novel biomarkers for the development of more targeted and effective therapies across many immune-mediated diseases. Our mission at Oncimmune is to enable precision medicine. We help our partners to discover novel biomarkers, drug targets and predict treatment efficacy through the application of our platform. We are able to do this by deploying our world class scientific team and our cutting-edge technology platform, built on years of experience in the field. Our aim is to make this an essential tool in drug discovery and development.
Oncimmune is headquartered in the UK, with its discovery and development facility based in Dortmund, Germany and a business development team based in the US and Europe.
For more information, visit www.oncimmune.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
